Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash & Equivalents (2019 - 2026)

Alx Oncology Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $22.4 million for Q4 2023.

  • On a quarterly basis, Cash & Equivalents fell 54.11% to $22.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $22.4 million, a 54.11% decrease, with the full-year FY2023 number at $22.4 million, down 54.11% from a year prior.
  • Cash & Equivalents hit $22.4 million in Q4 2023 for Alx Oncology Holdings, up from $19.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ALXO hit a ceiling of $434.2 million in Q4 2020 and a floor of $9.0 million in Q4 2019.
  • Historically, Cash & Equivalents has averaged $178.5 million across 5 years, with a median of $82.2 million in 2020.
  • Biggest five-year swings in Cash & Equivalents: soared 4715.56% in 2020 and later crashed 87.26% in 2022.
  • Tracing ALXO's Cash & Equivalents over 5 years: stood at $9.0 million in 2019, then soared by 4715.56% to $434.2 million in 2020, then decreased by 16.25% to $363.7 million in 2021, then plummeted by 86.58% to $48.8 million in 2022, then tumbled by 54.11% to $22.4 million in 2023.
  • Business Quant data shows Cash & Equivalents for ALXO at $22.4 million in Q4 2023, $19.6 million in Q3 2023, and $38.0 million in Q2 2023.